Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Cancer
Published in: Journal of Gastrointestinal Cancer 4/2011

01-12-2011 | Case Report

Hypoglycaemia in a 63-Year-Old Female with a Large, Recurrent, Metastatic Gastrointestinal Stromal Tumour (GIST)

Authors: Grace Tan, Melissa Teo, Su Pin Choo

Published in: Journal of Gastrointestinal Cancer | Issue 4/2011

Login to get access

Abstract

Introduction

Non-islet cell tumour-induced hypoglycaemia (NICTH) is rare, with few cases reported in patients with gastrointestinal stromal tumour (GIST).

Case Report

A 63-year-old Chinese female with known metastatic GIST presents with persistent hypoglycaemia. Investigations revealed a likely diagnosis of NICTH, and she underwent debulking surgery. There was complete resolution of her hypoglycaemia post-operatively

Discussion

NICTH should be considered in patients with GIST and hypoglycaemia. Surgical debulking is recommended as part of the management of NICTH.
Literature
1.
Nadler WH, Wolfer JA. Hepatogenic hypoglycemia associated with primary liver cell carcinoma. Arch Intern Med. 1929;44:700–5.
2.
Daughaday WH, Kapadia M. Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycaemia in patients with non-islet-cell tumours. Proc Natl Acad Sci USA. 1989;86(17):6778–82.PubMedCrossRef
3.
Guiteau J, Fanucchi M, Folpe A, Staley 3rd CA, et al. Hypoglycaemia in the setting of advanced gastrointestinal stromal tumour. Am Surg. 2006;72(12):1225–30.PubMed
4.
Escobar GA, Robinson WA, Nydam TL, Heiple DC, et al. Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer. 2007;17(7):13.CrossRef
5.
Pink D, Schoeler D, Lindner T, Thuss-Patience PC, et al. Severe hypoglycaemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumours: a report of two cases. J Clin Oncol. 2005;23(27):6809–11.PubMedCrossRef
6.
Teale JD, Wark G. The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia. Clin Endocrinol Oxf. 2004;60(4):457–60.PubMedCrossRef
7.
Hamberg P, Boonstra J, Doorn J, et al. Non-islet-cell tumour induced hypoglycaemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol. 2006;24(18):30–1.CrossRef
8.
Singh R, Grey A, Miller M, Gresnigt MG, et al. Non-hyperinsulinemic hypoglycemia in a patient with a gastrointestinal stromal tumor. Eur J Int Med. 2006;17(2):127–9.CrossRef
9.
Raut CP, Posner M, Desai J, Morgan JA, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24(15):2325–23231.PubMedCrossRef
10.
Sym SJ, Ryu MH, Lee JL, Chang HM, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008;98(1):27–33.PubMedCrossRef
Metadata
Title
Hypoglycaemia in a 63-Year-Old Female with a Large, Recurrent, Metastatic Gastrointestinal Stromal Tumour (GIST)
Authors
Grace Tan
Melissa Teo
Su Pin Choo
Publication date
01-12-2011
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 4/2011
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-010-9227-z

Other articles of this Issue 4/2011

Journal of Gastrointestinal Cancer 4/2011 Go to the issue

Mgmt. of Complex Cases in GI Oncology

A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management

Brief Communication

Pancreatic Resection for Metastatic Melanoma. Case Report and Review of the Literature

Case Report

Solitary Fibrous Tumor made Resectable after Successful Endovascular Embolization

Original Research

Immunohistochemical Detection of Autotaxin (ATX)/Lysophospholipase D (lysoPLD) in Submucosal Invasive Colorectal Cancer

Review Article

Non-Viral Causes of Hepatocellular Carcinoma

Original Research

Chemoradiation for Unresectable Gall Bladder Cancer: Time to Review Historic Nihilism?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits